Eli Lilly’s Retatrutide Cuts Body Weight by 17%, Lowers HbA1C in Phase 3 Diabetes Trial

Eli Lilly’s Phase 3 trial found that Retatrutide led to up to 16.8-17% body weight loss and a 1.9% reduction in HbA1C after 40 weeks in type 2 diabetes patients. These results surpass current drugs like Mounjaro, highlighting Retatrutide’s potential as a dual-action treatment for diabetes and obesity. The next step is regulatory review and potential US market approval, which could reshape diabetes care.